China Isotope & Radiation Corporation (1763.HK) Stock

About China Isotope & Radiation Corporation

China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of nuclides, diagnostic, and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. The company operates through five segments: Nuclear Medicines; Radioactive Source Products; Irradiation; Nuclear Medical Equipment and Related Services; and Other Businesses. The Nuclear Medicines segment engages in research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals, urea breath test diagnostic kits, test analyzers, and other products. The Radioactive Source Products segment sells medical and industrial radioactive sources products and related technical services. The Irradiation segment offers irradiation services to manufacturers of medical devices, pharmaceuticals, cosmetics, and food for sterilization, and provides design, manufacturing, and installation of gamma ray irradiation facilities and related technical services. The Nuclear Medical Equipment and Related Services segment sells nuclear medical equipment and provides related maintenance services. The Other Businesses segment provides trade services for nuclear technology industry applications, medical product applications, technical services, and sales of medical devices. This segment also offers independent clinical laboratory services for nuclear technology industry applications and medical product applications; and provides radioactive sources, medical nuclides, imported radiopharmaceuticals, nuclear instruments and devices, medical equipment and other products. The company was incorporated in 1983 and is headquartered in Beijing, China. China Isotope & Radiation Corporation operates as a subsidiary of China National Nuclear Corporation.

China Isotope & Radiation Corporation is led by CEO Junqi Zhang, employs 3,578 people, headquartered in Beijing, CN, publicly traded since 2018.

China Isotope & Radiation Corporation (1763.HK) stock trades at $16.95 with a market capitalization of $5.42B. The stock is valued at a price-to-earnings (P/E) ratio of 14.49, price-to-book of 0.89, price-to-sales of 0.75. Over the past 52 weeks the stock has ranged between $15.20 and $25.00, and currently trades 32.2% below its 52-week high. It pays a dividend yielding 2.03%.

On profitability, China Isotope & Radiation Corporation generates a return on equity (ROE) of 8.37%, an operating margin of 13.28%, a net profit margin of 4.56%.

Official website: www.circ.com.cn